Coherus CEO Denny Lanfear (L) and Junshi CEO Li Ning
Two months after CRL, FDA accepts Coherus, Junshi's resubmission for PD-1 studied in China
China-only clinical data has not fared well before the FDA this year. But in one case, the regulatory agency might be willing to budge a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
